Skip to main content
Immunovia logo

Immunovia — Investor Relations & Filings

Ticker · IMMNOV ISIN · SE0006091997 LEI · 549300KHWL6KK1XGUO81 ST Human health and social work activities
Open in API
Filings indexed 377 across all filing types
Latest filing 2019-11-29 Regulatory Filings
Country SE Sweden
Listing ST IMMNOV

About Immunovia

https://immunovia.com/

Immunovia is a diagnostics company focused on revolutionizing the early detection of pancreatic cancer. Its primary product is the PancreaSure test, a simple blood test designed to detect pancreatic cancer at Stage 1 and 2 with high accuracy. The test is intended for annual surveillance of individuals at elevated risk due to family history or genetic mutations. PancreaSure functions by detecting proteins and other biomarkers indicative of pancreatic cancer growth. The company's mission is to improve survival rates for this highly lethal cancer by enabling diagnosis at its earliest, most treatable stages, offering a convenient alternative to invasive imaging procedures.

Recent filings

Filing Released Lang Actions
Immunovia continues with next stage of the Lung Cancer Project together with Global Pharma Partner
Regulatory Filings Classification · 95% confidence The document is a 'PRESS RELEASE' announcing that Immunovia AB's Lung Cancer collaboration with a global pharmaceutical partner is entering the next stage, involving testing and analysis scheduled to finish in Q2 2020. It details the progress of a scientific/clinical study and its implications for the company's technology platform (IMMray™). This type of announcement, which is not a formal financial report (like 10-K or IR), nor a management change (MANG), nor a dividend notice (DIV), nor a specific regulatory filing like insider trading (DIRS) or capital change (CAP), falls best under a general regulatory announcement or news release category. Since it is a specific operational update that doesn't fit the highly specific financial/governance codes, the most appropriate general category is Regulatory Filings (RNS), which serves as a fallback for miscellaneous regulatory news releases.
2019-11-29 English
Immunovia fortsätter med nästa fas i lungcancerprojektet tillsammans med global läkemedelspartner
Regulatory Filings Classification · 95% confidence The document is titled "PRESSMEDDELANDE" (Press Release) and announces a specific business development: Immunovia is moving into the next phase of its lung cancer project collaboration with a global pharmaceutical partner. It details the next steps (testing and analysis timeline) and the goal of the collaboration. This type of announcement, which is a formal update on a specific operational or strategic event, is best classified as a general Regulatory Filing (RNS) or potentially an announcement related to ongoing research/development, but given the options, RNS serves as the best fit for a standard press release detailing operational progress that isn't a core financial report (like 10-K, ER, or IR) or a specific corporate action (like DIV or CAP). Since it is a formal announcement published under EU Market Abuse Regulation, RNS is appropriate as a broad regulatory disclosure.
2019-11-29 Swedish
Correction: Immunovia Interim Report, January-September 2019
Interim / Quarterly Report Classification · 100% confidence The document is titled 'Interim Report January-September 2019' for Immunovia AB. It contains comprehensive financial statements, including consolidated income statements, balance sheets, and cash flow statements, as well as management commentary and an auditor's review. It is a full interim report, not an announcement or a summary, and meets the criteria for the 'Interim / Quarterly Report' category. 9M 2019
2019-11-08 English
Korrigerad version: Immunovia delårsrapport januari-september 2019
Interim / Quarterly Report Classification · 100% confidence The document is a 'Delårsrapport' (Interim Report) for the period January-September 2019. It contains comprehensive financial statements, including income statements, key performance indicators (Nyckeltal), and detailed management commentary on business developments, research progress, and future outlook. It is not a short announcement but a full quarterly report, fitting the definition of an Interim/Quarterly Report (IR). 9M 2019
2019-11-08 Swedish
Interim / Quarterly Report 2019
Interim / Quarterly Report Classification · 100% confidence The document is titled 'Delårsrapport jan-sep 2019' (Interim Report Jan-Sep 2019) for Immunovia AB. It contains comprehensive financial tables (income statement, key ratios), management commentary, and details on business developments for the specified period. It is a full interim report, not an announcement or a summary, and meets the criteria for an Interim/Quarterly Report. 9M 2019
2019-11-08 Swedish
Interim / Quarterly Report 2019
Interim / Quarterly Report Classification · 100% confidence The document is explicitly titled 'Interim Report January-September 2019' for Immunovia AB. It contains comprehensive financial statements (income statement, balance sheet, cash flow), key performance indicators, management commentary (CEO's statement), and an auditor's review section. It meets the criteria for an Interim/Quarterly Report (IR) as it provides substantive financial data for a period shorter than a full fiscal year. 9M 2019
2019-11-08 English

Browse filings by year

13 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.